BISPECIFIC ANTI-MERTK AND ANTI-PDL1 ANTIBODIES AND METHODS OF USE THEREOF

1 . A bispecific antibody that binds to human Mer Tyrosine Kinase (MerTK) and programmed death-ligand 1 (PDL1), wherein the bispecific antibody contains a first antigen-binding domain that binds to human MerTk and a second antigen-binding domain that binds to PDL1.

2 . The antibody of claim 1 , wherein the first antigen-binding domain binds to the Ig1 domain of MerTK protein.

3 . The bispecific antibody of claim 1 or 2 , wherein the first antigen binding domain competitively inhibits binding to the MerTK of an antibody comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a variable light chain comprising the amino acid sequence of SEQ ID NO:10.

4 . The bispecific antibody of any one of claims 1-3 , wherein the first antigen binding domain binds to the same MerTK epitope as an antibody comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a variable light chain comprising the amino acid sequence of SEQ ID NO:10.

5 . The bispecific antibody of any one of claims 1-4 , wherein the first antigen binding domain an HVR-H1 comprising amino acids 31-35 of SEQ ID NO:9, an HVR-H2 comprising amino acids 50-66 of SEQ ID NO:9, an HVR-H3 comprising amino acids 99-109 of SEQ ID NO:9, an HVR-L1 comprising amino acids 24-34 of SEQ ID NO:10, an HVR-L2 comprising amino acids 50-56 of SEQ ID NO:10, and an HVR-L3 comprising amino acids 89-97 of SEQ ID NO:10.

6 . The bispecific antibody of any one of claims 1-4 , wherein the first antigen binding domain comprises the HVRs of the 16.2 antibody, optionally wherein the HVRs are the Kabat-defined HVRs, the Chothia-defined HVRs, the AbM-defined HVRs, or the contact-defined HVRs

7 . The bispecific antibody of any one of claims 1-6 , wherein the first antigen binding domain comprises a variable heavy chain comprising an amino acid sequence that is at least 85%, at least 90%, or at least 95% identical to the amino acid sequence of SEQ ID NO:9.

8 . The bispecific antibody of any one of claims 1-7 , wherein the first antigen binding domain comprises a variable light chain comprising an amino acid sequence that is at least 85%, at least 90%, or at least 95% identical to the amino acid sequence of SEQ ID NO:10.

9 . The bispecific antibody of any one of claims 1-8 , wherein the first antigen binding domain comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:9 and/or a variable light chain comprising the amino acid sequence of SEQ ID NO:10.

10 . The bispecific antibody of claim 1 or 2 , wherein the first antigen binding domain binds to the same MerTK epitope as an antibody comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 14.

11 . The bispecific antibody of any one of claims 1, 2 and 10 , wherein the first antigen binding domain competitively inhibits binding to the MerTK of an antibody comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and a variable light chain comprising the amino acid sequence of SEQ ID NO:14.

12 . The bispecific antibody of any one of claims 1, 2, 10, and 11 , wherein the first antigen binding domain comprises an HVR-H1 comprising amino acids 31-35 of SEQ ID NO:13, an HVR-H2 comprising amino acids 50-66 of SEQ ID NO:13, an HVR-H3 comprising amino acids 99-108 of SEQ ID NO:13, an HVR-L1 comprising amino acids 24-34 of SEQ ID NO:14, an HVR-L2 comprising amino acids 50-56 of SEQ ID NO:14, and an HVR-L3 comprising amino acids 89-97 of SEQ ID NO: 14.

13 . The bispecific antibody of any one of claims 1, 2, 10 and 11 , wherein the first antigen binding domain comprises the HVRs of the 13.11 antibody, optionally wherein the HVRs are the Kabat-defined HVRs, the Chothia-defined HVRs, the AbM-defined HVRs, or the contact-defined HVRs.

14 . The bispecific antibody of any one of claims 1, 2, and 10-13 , wherein the first antigen binding domain comprises a variable heavy chain comprising an amino acid sequence that is at least 85%, at least 90%, or at least 95% identical to the amino acid sequence of SEQ ID NO:13.

15 . The bispecific antibody of any one of claims 1, 2, and 10-14 , wherein the first antigen binding domain comprises a variable light chain comprising an amino acid sequence that is at least 85%, at least 90%, or at least 95% identical to the amino acid sequence of SEQ ID NO: 14.

16 . The bispecific antibody of any one of claims 1, 2, and 10-15 , wherein the first antigen binding domain comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:13 and a variable light chain comprising the amino acid sequence of SEQ ID NO:14.

17 . The bispecific antibody of any one of claims 1-16 , wherein the second antigen binding domain binds to the same PDL1 epitope as an antibody comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO:52 and a variable light chain comprising the amino acid sequence of SEQ ID NO:53.

18 . The bispecific antibody of any one of claims 1-17 , wherein the second antigen binding domain competitively inhibits binding to the PDL1 of an antibody comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO:52 and a variable light chain comprising the amino acid sequence of SEQ ID NO:53.

19 . The bispecific antibody of any one of claims 1-18 , wherein the second antigen binding domain comprises an HVR-H1 comprising amino acids 31-35 of SEQ ID NO:52, an HVR-H2 comprising amino acids 50-66 of SEQ ID NO:52, an HVR-H3 comprising amino acids 99-107 of SEQ ID NO:52, an HVR-L1 comprising amino acids 24-34 of SEQ ID NO:53, an HVR-L2 comprising amino acids 50-56 of SEQ ID NO:53, and an HVR-L3 comprising amino acids 89-97 of SEQ ID NO:53

20 . The bispecific antibody of any one of claims 1-18 , wherein the second antigen binding domain comprises the HVRs of the atezolizumab antibody, optionally wherein the HVRs are the Kabat-defined HVRs, the Chothia-defined HVRs, the AbM-defined HVRs, or the contact-defined HVRs.

21 . The bispecific antibody of any one of claims 1-20 , wherein the second antigen binding domain comprises a variable heavy chain comprising an amino acid sequence that is at least 85%, at least 90%, or at least 95% identical to the amino acid sequence of SEQ ID NO:52.

22 . The bispecific antibody of any one of claims 1-21 , wherein the second antigen binding domain comprises a variable light chain comprising an amino acid sequence that is at least 85%, at least 90%, or at least 95% identical to the amino acid sequence of SEQ ID NO:53.

23 . The bispecific antibody of any one of claims 1-22 , wherein the second antigen binding domain comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:52 and a variable light chain comprising the amino acid sequence of SEQ ID NO:53.

24 . The bispecific antibody of any one of claims 1-23 , wherein the bispecific antibody is of the IgG class, the IgM class, or the IgA class.

25 . The bispecific antibody of claim 24 , wherein the bispecific antibody is of the IgG class, optionally wherein the bispecific antibody has an IgG1, an IgG2, or an IgG4 isotype.

26 . The bispecific antibody of claim 25 , wherein the bispecific antibody is an IgG1 antibody.

27 . The bispecific antibody of claim 25 , wherein the bispecific antibody is an IgG4 antibody.

28 . The bispecific antibody of any one of claims 1-27 , wherein the bispecific antibody (i) has two arms comprising different antigen-binding domains, (ii) is a single chain antibody that has specificity to two different epitopes, (iii) is a chemically-linked bispecific (Fab′)2 fragment, (iv) is a fusion of two single chain diabodies resulting in a tetravalent bispecific antibody that has two binding sites for each of the target antigens, (v) is a combination of scFvs with a diabody resulting in a multivalent molecule, (vi) comprises two scFvs fused to both termini of a human Fab-arm, or (vii) is a diabody.

29 . The bispecific antibody of any one of claims 1-27 , wherein the bispecific antibody is a kappa-lambda body, a dual-affinity re-targeting molecule (DART), a knob-in-hole antibody, a strand-exchange engineered domain body (SEEDbody), or a DuoBody.

30 . The bispecific antibody of any one of claims 1-29 , wherein the bispecific antibody comprises an Fc region comprising a first polypeptide and a second polypeptide wherein:

(a) the first polypeptide comprises the amino acid substitution T366Y, and the second polypeptide comprises the amino acid substation Y407T;

(b) the first polypeptide comprises the amino acid substitution T366W, and the second polypeptide comprises the amino acid substitutions T366S, L368W, and Y407V;

(c) the first polypeptide comprises the amino acid substitution T366W, and the second polypeptide comprises the amino acid substitutions T366S, L368A, and Y407V;

(d) the first polypeptide comprises the amino acid substitutions T366W, and S354C and the second polypeptide comprises the amino acid substitutions T366S, L368A, Y407V, and Y349C;

(e) the first polypeptide comprises the amino acid substitutions T350V, L351Y, F405A, Y407V, and the second polypeptide comprises the amino acid substitutions T350V, T366L, K392L, and T394W;

(f) the first polypeptide comprises the amino acid substitutions K360D, D399M, and Y407A, and the second polypeptide comprises the amino acid substitutions E345R, Q347R, T366V, and K409V;

(g) the first polypeptide comprises the amino acid substitutions K409D and K392D, and the second polypeptide comprises the amino acid substitutions D399K and E356K;

(h) the first polypeptide comprises the amino acid substitutions K360E and K409W, and the second polypeptide comprises the amino acid substitutions Q347R, D399V, and F405T;

(i) the first polypeptide comprises the amino acid substitutions L360E, K409W, and Y349C, and the second polypeptide comprises the amino acid substitutions Q347R, D399V, F405T, and S354C; or

(j) the first polypeptide comprises the amino acid substitutions K370E and K409W, and the second polypeptide comprises the amino acid substitutions E357N, D399V, and F405T;

wherein the substitution is according to EU numbering.

31 . The bispecific antibody of any one of claims 1-30 , wherein the bispecific antibody comprises a knob mutation and a hole mutation.

32 . The bispecific antibody of claim 31 , wherein the knob mutation comprises the amino acid substitution T366W according to EU numbering.

33 . The bispecific antibody of claim 31 or 32 , wherein the hole mutation comprises the amino acids substitutions T366S, L368A, and Y407V according to EU numbering.

34 . The bispecific antibody of any one of claims 1-33 , wherein the bispecific antibody comprises an Fc region comprising an amino acid substitution, addition, or deletion that promotes heterodimerization.

35 . The bispecific antibody of any one of claims 1-25, and 27-34 , wherein the bispecific antibody comprises the amino acid substitution S228P according to EU numbering.

36 . The bispecific antibody of any one of claims 1-35 , wherein the bispecific antibody comprises the amino acid substitutions L234A, L235A, and P331S (LALAPS) accordingly to EU numbering.

37 . The bispecific antibody of any one of claims 1-36 , wherein the bispecific antibody comprises the amino acid substitutions N325S and L328F (NSLF) according to EU numbering.

38 . The bispecific antibody of any one of claims 1-9, 17-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO:17 or the amino acid sequence of SEQ ID NO:17.

39 . The bispecific antibody of any one of claims 1-9, 17-26, 28, 29, and 36 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO:18 or the amino acid sequence of SEQ ID NO: 18.

40 . The bispecific antibody of any one of claims 1-9, 17-26, 28, 29, and 37 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO: 19 or the amino acid sequence of SEQ ID NO: 19.

41 . The bispecific antibody of any one of claims 1-9, 17-25, 27, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-446 of SEQ ID NO:20 or the amino acid sequence of SEQ ID NO:20.

42 . The bispecific antibody of any one of claims 1-9, 17-26, and 28-34 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-453 of SEQ ID NO:32 or the amino acid sequence of SEQ ID NO:32.

43 . The bispecific antibody of any one of claims 1-9, 17-26, 28-34, and 36 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO:33 or the amino acid sequence of SEQ ID NO:33.

44 . The bispecific antibody of any one of claims 1-9, 17-26, 28-34, and 37 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO:34 or the amino acid sequence of SEQ ID NO:34.

45 . The bispecific antibody of any one of claims 1-9, 17-25, and 27-34 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-446 of SEQ ID NO:35 or the amino acid sequence of SEQ ID NO:35.

46 . The bispecific antibody of any one of claims 1-9, 17-25, and 27-35 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-446 of SEQ ID NO:36 or the amino acid sequence of SEQ ID NO:36.

47 . The bispecific antibody of any one of claims 1-9, 17-26, 28, 29, 36 and 37 , wherein the bispecific antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:21.

48 . The bispecific antibody any one of claims 1, 2, 10-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:22 or the amino acid sequence of SEQ ID NO:22.

49 . The bispecific antibody of any one of claims 1, 2, 10-26, 28, 29, and 36 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:23 or the amino acid sequence of SEQ ID NO:23.

50 . The bispecific antibody of any one of claims 1, 2, 10-26, 28, 29, and 37 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:24 or the amino acid sequence of SEQ ID NO:24.

51 . The bispecific antibody of any one of claims 1, 2, 10-25, and 27-29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-445 of SEQ ID NO:25 or the amino acid sequence of SEQ ID NO:25.

52 . The bispecific antibody of any one of claims 1, 2, 10-26, and 28-34 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:37 or the amino acid sequence of SEQ ID NO:37.

53 . The bispecific antibody of any one of claims 1, 2, 10-26, 28-34, and 36 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:38 or the amino acid sequence of SEQ ID NO:38.

54 . The bispecific antibody of any one of claims 1, 2, 10-26, 28-34, and 37 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:39 or the amino acid sequence of SEQ ID NO:39.

55 . The bispecific antibody of any one of claims 1, 2, 10-25, and 27-34 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-445 of SEQ ID NO:40 or the amino acid sequence of SEQ ID NO:40.

56 . The bispecific antibody of any one of claims 1, 2, 10-25, and 27-35 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-445 of SEQ ID NO:41 or the amino acid sequence of SEQ ID NO:41.

57 . The bispecific antibody of any one of claims 1, 2, 10-26, 28, 29, 36, and 37 , wherein the bispecific antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:26.

58 . The bispecific antibody of any one of claims 1-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-447 of SEQ ID NO:27 or the amino acid sequence of SEQ ID NO:27.

59 . The bispecific antibody of any one of claims 1-26, 28, 29, and 36 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-447 of SEQ ID NO:28 or the amino acid sequence of SEQ ID NO:28.

60 . The bispecific antibody of any one of claims 1-26, 28, 29, and 37 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-447 of SEQ ID NO:29 or the amino acid sequence of SEQ ID NO:29.

61 . The bispecific antibody of any one of claims 1-25 and 27-29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-444 of SEQ ID NO:30 or the amino acid sequence of SEQ ID NO:30.

62 . The bispecific antibody of any one of claims 1-26 and 28-34 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-447 of SEQ ID NO:42 or the amino acid sequence of SEQ ID NO:42.

63 . The bispecific antibody of any one of claims 1-26, 28-34, and 36 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-447 of SEQ ID NO:43 or the amino acid sequence of SEQ ID NO:43.

64 . The bispecific antibody of any one of claims 1-26, 28-34, and 37 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-447 of SEQ ID NO:44 or the amino acid sequence of SEQ ID NO:44.

65 . The bispecific antibody of any one of claims 1-25 and 27-34 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-444 of SEQ ID NO:45 or the amino acid sequence of SEQ ID NO:45.

66 . The bispecific antibody of any one of claims 1-25 and 27-35 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-444 of SEQ ID NO:46 or the amino acid sequence of SEQ ID NO:46.

67 . The bispecific antibody of any one of claims 1-26, 28, 29, 36, and 37 , wherein the bispecific antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:31.

68 . The bispecific antibody of any one of claims 1-26, 28-34, 36-37, 47, 57, and 67 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:47.

69 . The bispecific antibody of any one of claims 1-26, 28-34, 36-37, 47, 57, and 67 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:48.

70 . The bispecific antibody of any one of claims 1-26, 28-34, 36-37, 47, 57, and 67 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:49.

71 . The bispecific antibody of any one of claims 1-26, 28-34, 36-37, 47, 57, and 67 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:50.

72 . The bispecific antibody of any one of claims 1-26, 28-34, 36-37, 47, 57, and 67 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:51.

73 . The bispecific antibody of any one of claims 1-9, 17-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO:17 or the amino acid sequence of SEQ ID NO:17, a light chain comprising the amino acid sequence of SEQ ID NO:21, a heavy chain comprising amino acids 1-447 of SEQ ID NO:27 or the amino acid sequence of SEQ ID NO:27 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

74 . The bispecific antibody of any one of claims 1-9, 17-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO:18 or the amino acid sequence of SEQ ID NO:18, a light chain comprising the amino acid sequence of SEQ ID NO:21, a heavy chain comprising amino acids 1-447 of SEQ ID NO:28 or the amino acid sequence of SEQ ID NO:28 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

75 . The bispecific antibody of any one of claims 1-9, 17-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO: 19 or the amino acid sequence of SEQ ID NO: 19, a light chain comprising the amino acid sequence of SEQ ID NO:21, a heavy chain comprising amino acids 1-447 of SEQ ID NO:29 or the amino acid sequence of SEQ ID NO:29 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

76 . The bispecific antibody of any one of claims 1-9, 17-25, and 27-29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-446 of SEQ ID NO:20 or the amino acid sequence of SEQ ID NO:20, a light chain comprising the amino acid sequence of SEQ ID NO:21, a heavy chain comprising amino acids 1-444 of SEQ ID NO:30 or the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

77 . The bispecific antibody of any one of claims 1, 2, 10-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:22 or the amino acid sequence of SEQ ID NO:22, a light chain comprising the amino acid sequence of SEQ ID NO:26, a heavy chain comprising amino acids 1-447 of SEQ ID NO:27 or the amino acid sequence of SEQ ID NO:27 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

78 . The bispecific antibody of any one of claims 1, 2, 10-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:23 or the amino acid sequence of SEQ ID NO:23, a light chain comprising the amino acid sequence of SEQ ID NO:26, a heavy chain comprising amino acids 1-447 of SEQ ID NO:28 or the amino acid sequence of SEQ ID NO:28 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

79 . The bispecific antibody of any one of claims 1, 2, 10-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:24 or the amino acid sequence of SEQ ID NO:24, a light chain comprising the amino acid sequence of SEQ ID NO:26, a heavy chain comprising amino acids 1-447 of SEQ ID NO:29 or the amino acid sequence of SEQ ID NO:29 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

80 . The bispecific antibody of any one of claims 1, 2, 10-25, and 27-29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-445 of SEQ ID NO:25 or the amino acid sequence of SEQ ID NO:25, a light chain comprising the amino acid sequence of SEQ ID NO:26, a heavy chain comprising amino acids 1-444 of SEQ ID NO:30 or the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

81 . The bispecific antibody of any one of claims 1-9, 17-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-453 of SEQ ID NO:32 or the amino acid sequence of SEQ ID NO:32, a light chain comprising the amino acid sequence of SEQ ID NO:21, a heavy chain comprising amino acids 1-447 of SEQ ID NO:42 or the amino acid sequence of SEQ ID NO:42 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

82 . The bispecific antibody of any one of claims 1-9, 17-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO:33 or the amino acid sequence of SEQ ID NO:33, a light chain comprising the amino acid sequence of SEQ ID NO:21, a heavy chain comprising amino acids 1-447 of SEQ ID NO:43 or the amino acid sequence of SEQ ID NO:43 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

83 . The bispecific antibody of any one of claims 1-9, 17-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-449 of SEQ ID NO:34 or the amino acid sequence of SEQ ID NO:34, a light chain comprising the amino acid sequence of SEQ ID NO:21, a heavy chain comprising amino acids 1-447 of SEQ ID NO:44 or the amino acid sequence of SEQ ID NO:44 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

84 . The bispecific antibody of any one of claims 1-9, 17-25, and 27-29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-446 of SEQ ID NO:35 or the amino acid sequence of SEQ ID NO:35, a light chain comprising the amino acid sequence of SEQ ID NO:21, a heavy chain comprising amino acids 1-444 of SEQ ID NO:45 or the amino acid sequence of SEQ ID NO:45 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

85 . The bispecific antibody of any one of claims 1-9, 17-25, and 27-29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-446 of SEQ ID NO:36 or the amino acid sequence of SEQ ID NO:36, a light chain comprising the amino acid sequence of SEQ ID NO:21, a heavy chain comprising amino acids 1-444 of SEQ ID NO:46 or the amino acid sequence of SEQ ID NO:46 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

86 . The bispecific antibody of any one of claims 1, 2, 10-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:37 or the amino acid sequence of SEQ ID NO:37, a light chain comprising the amino acid sequence of SEQ ID NO:26, a heavy chain comprising amino acids 1-447 of SEQ ID NO:42 or the amino acid sequence of SEQ ID NO:42 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

87 . The bispecific antibody of any one of claims 1, 2, 10-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:38 or the amino acid sequence of SEQ ID NO:38, a light chain comprising the amino acid sequence of SEQ ID NO:26, a heavy chain comprising amino acids 1-447 of SEQ ID NO:43 or the amino acid sequence of SEQ ID NO:43 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

88 . The bispecific antibody of any one of claims 1, 2, 10-26, 28, and 29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-448 of SEQ ID NO:39 or the amino acid sequence of SEQ ID NO:39, a light chain comprising the amino acid sequence of SEQ ID NO:26, a heavy chain comprising amino acids 1-447 of SEQ ID NO:44 or the amino acid sequence of SEQ ID NO:44 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

89 . The bispecific antibody of any one of claims 1, 2, 10-25, and 27-29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-445 of SEQ ID NO:40 or the amino acid sequence of SEQ ID NO:40, a light chain comprising the amino acid sequence of SEQ ID NO:26, a heavy chain comprising amino acids 1-444 of SEQ ID NO:45 or the amino acid sequence of SEQ ID NO:45 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

90 . The bispecific antibody of any one of claims 1, 2, 10-25, and 27-29 , wherein the bispecific antibody comprises a heavy chain comprising amino acids 1-445 of SEQ ID NO:41 or the amino acid sequence of SEQ ID NO:41, a light chain comprising the amino acid sequence of SEQ ID NO:26, a heavy chain comprising amino acids 1-444 of SEQ ID NO:46 or the amino acid sequence of SEQ ID NO:46 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

91 . The bispecific antibody of any one of claims 1-90 , wherein the bispecific antibody is capable of binding MerTK and PDL1 simultaneously.

92 . The bispecific antibody of any one of claims 1-91 , wherein the bispecific antibody reduces efferocytosis by a phagocytic cell.

93 . The bispecific antibody of claim 92 , wherein the bispecific antibody reduces efferocytosis with an IC50 value of about 4 nM to about 16 nM.

94 . The bispecific antibody of claim 93 , wherein the bispecific antibody reduces efferocytosis with an IC50 value of about 4 nM to about 5 nM, or about 15 nM to about 16 nM.

95 . The bispecific antibody of claim 93 or 49 , wherein the phagocytic cell is a macrophage, a tumor-associated macrophage, or a dendritic cell.

96 . The bispecific antibody of claim 95 , wherein the phagocytic cell is a macrophage.

97 . The bispecific antibody of any one of claims 1-96 , wherein the bispecific antibody inhibits tumor growth.

98 . The bispecific antibody of any one of claims 1-97 , wherein the bispecific antibody reduces binding of ProS to MerTK.

99 . The bispecific antibody of any one of claims 1-98 , wherein the bispecific antibody reduces binding of Gas6 to MerTK.

100 . The bispecific antibody of any one of claims 1-99 , wherein the bispecific antibody reduces binding of ProS to MerTK and reduces the binding of Gas6 to MerTK.

101 . The bispecific antibody of any one of claims 1-100 , wherein the bispecific antibody binds to human MerTK with a binding affinity of about 2 nM to about 30 nM, optionally wherein the bispecific antibody binds to human MerTK with a binding affinity of about 2 nM or about 30 nM.

102 . The bispecific antibody of any one of claims 1-101 , wherein the bispecific antibody also binds to cynomolgus monkey MerTk.

103 . The bispecific antibody of claim 102 , wherein the bispecific antibody binds to cynomolgus MerTK with a binding affinity of about 2 nM to about 30 nM, optionally wherein the bispecific antibody binds to cynomolgus MerTK with a binding affinity of about 2 nM or about 30 nM.

104 . The bispecific antibody of any one of claims 1-103 , wherein the bispecific antibody also binds to murine MerTK.

105 . The bispecific antibody of claim 104 , wherein the bispecific antibody binds to murine MerTK with a binding affinity of about 40 nM.

106 . The bispecific antibody of any one of claims 1-103 , wherein the bispecific antibody does not bind to murine MerTK.

107 . The bispecific antibody of any one of claims 1-106 , wherein the bispecific antibody reduces Gas6-mediated phosphorylation of AKT.

108 . The bispecific antibody of any one of claims 1-107 , wherein the bispecific antibody reduces Gas6-mediated phosphorylation of AKT with an IC50 value of about 9 nM to about 13 nM, optionally wherein the bispecific antibody reduces Gas6-mediated phosphorylation of AKT with an IC50 value of about 9 nM or about 13 nM.

109 . The bispecific antibody of any one of claims 1-108 , wherein the bispecific antibody is a murine antibody, a human antibody, a humanized antibody, a monoclonal antibody, a multivalent antibody, a conjugated antibody, or a chimeric antibody.

110 . A humanized form of the bispecific antibody of any one of claims 1-109 .

111 . The bispecific antibody of any one of claims 1-110 , wherein the bispecific antibody is a recombinant antibody.

112 . The bispecific antibody of any one of claims 1-111 , wherein the bispecific antibody is an isolated antibody.

113 . An isolated nucleic acid comprising a nucleic acid sequence encoding the bispecific antibody of any one of claims 1-112 .

114 . A vector comprising the nucleic acid of claim 113 .

115 . An isolated host cell comprising the nucleic acid of claim 113 or the vector of claim 114 .

116 . An isolated host cell comprising (i) a nucleic acid comprising a nucleic acid sequence encoding the variable heavy chain of the first antigen binding domain of the bispecific antibody of any one of claims 1-112 ; (ii) a nucleic acid comprising a nucleic acid sequence encoding the variable light chain of the first antigen binding domain of the bispecific antibody; (iii) a nucleic acid comprising a nucleic acid sequence encoding the variable heavy chain of the second antigen binding domain of the bispecific antibody; and (iv) a nucleic acid comprising a nucleic acid sequence encoding the variable light chain of the second antigen binding domain of the bispecific antibody;

117 . An isolated host cell comprising (i) a nucleic acid comprising a nucleic acid sequence encoding the heavy chain comprising the variable heavy chain the first antigen binding domain of the bispecific antibody of any one of claims 1-112 ; (ii) a nucleic acid comprising a nucleic acid sequence encoding a light chain comprising the variable light chain of the first antigen binding domain of the bispecific antibody; (iii) a nucleic acid comprising a nucleic acid sequence encoding a heavy chain comprising the variable heavy chain of the second antigen binding domain of the bispecific antibody; and (iv) a nucleic acid comprising a nucleic acid sequence encoding a light chain comprising the variable light chain of the second antigen binding domain of the bispecific antibody.

118 . A method of producing a bispecific antibody that binds to human MerTK and PDL1, the method comprising culturing the cell of any one of claims 115-117 so that the bispecific antibody is produced.

119 . The method of claim 118 , further comprising recovering the bispecific antibody produced by the cell.

120 . A bispecific antibody produced by the method of claim 118 or 119 .

121 . A pharmaceutical composition comprising the bispecific antibody of any one of claim 1-112 or 120 and a pharmaceutically acceptable carrier.

122 . A method of treating cancer in an individual, the method comprising administering to an individual a therapeutically effective amount of the bispecific antibody of any one of claim 1-112 or 120 or the pharmaceutical composition of claim 121 .

123 . The method of claim 122 , wherein the cancer is colon cancer, ovarian cancer, liver cancer, or endometrial cancer.

124 . The method of claim 122 or 123 , wherein the administration does not lead to a retinal pathology in the individual.

125 . A method for detecting MerTK in a sample comprising contacting said sample with the bispecific antibody of any one of claim 1-112 or 120 .